Margaux M Salas1, John L Clifford1, Jessica R Hayden1, Michael J Iadarola2, Dayna L Averitt3. 1. Pain Management Research Area, United States Army Institute of Surgical Research, JBSA Fort Sam Houston, Texas. 2. Department of Perioperative Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland. 3. Department of Biology, Texas Woman's University, Denton, Texas, USA.
Abstract
OBJECTIVE: Opioid-based analgesics are a major component of the lengthy pain management of burn patients, including military service members, but are problematic due to central nervous system-mediated side effects. Peripheral analgesia via targeted ablation of nociceptive nerve endings that express the transient receptor potential vanilloid channel 1 (TRPV1) may provide an improved approach. We hypothesized that local injection of the TRPV1 agonist resiniferatoxin (RTX) would produce long-lasting analgesia in a rat model of pain associated with burn injury. METHODS: Baseline sensitivities to thermal and mechanical stimuli were measured in male and female Sprague-Dawley rats. Under anesthesia, a 100 °C metal probe was placed on the right hind paw for 30 seconds, and sensitivity was reassessed 72 hours following injury. Rats received RTX (0.25 μg/100 μL; ipl) into the injured hind paw, and sensitivity was reassessed across three weeks. Tissues were collected from a separate group of rats at 24 hours and/or one week post-RTX for pathological analyses of the injured hind paw, dorsal spinal cord c-Fos, and primary afferent neuropeptide immunoreactivity. RESULTS: Local RTX reversed burn pain behaviors within 24 hours, which lasted through recovery at three weeks. At one week following RTX, decreased c-Fos and primary afferent neuropeptide immunoreactivities were observed in the dorsal horn, while plantar burn pathology was unaltered. CONCLUSIONS: These results indicate that local RTX induces long-lasting analgesia in a rat model of pain associated with burn. While opioids are undesirable in trauma patients due to side effects, RTX may provide valuable long-term, nonopioid analgesia for burn patients. 2016 American Academy of Pain Medicine. This work is written by US Government employees and is in the public domain in the US.
OBJECTIVE: Opioid-based analgesics are a major component of the lengthy pain management of burn patients, including military service members, but are problematic due to central nervous system-mediated side effects. Peripheral analgesia via targeted ablation of nociceptive nerve endings that express the transient receptor potential vanilloid channel 1 (TRPV1) may provide an improved approach. We hypothesized that local injection of the TRPV1 agonist resiniferatoxin (RTX) would produce long-lasting analgesia in a rat model of pain associated with burn injury. METHODS: Baseline sensitivities to thermal and mechanical stimuli were measured in male and female Sprague-Dawley rats. Under anesthesia, a 100 °C metal probe was placed on the right hind paw for 30 seconds, and sensitivity was reassessed 72 hours following injury. Rats received RTX (0.25 μg/100 μL; ipl) into the injured hind paw, and sensitivity was reassessed across three weeks. Tissues were collected from a separate group of rats at 24 hours and/or one week post-RTX for pathological analyses of the injured hind paw, dorsal spinal cord c-Fos, and primary afferent neuropeptide immunoreactivity. RESULTS: Local RTX reversed burn pain behaviors within 24 hours, which lasted through recovery at three weeks. At one week following RTX, decreased c-Fos and primary afferent neuropeptide immunoreactivities were observed in the dorsal horn, while plantar burn pathology was unaltered. CONCLUSIONS: These results indicate that local RTX induces long-lasting analgesia in a rat model of pain associated with burn. While opioids are undesirable in trauma patients due to side effects, RTX may provide valuable long-term, nonopioid analgesia for burn patients. 2016 American Academy of Pain Medicine. This work is written by US Government employees and is in the public domain in the US.
Authors: Daniel J Cavanaugh; Alexander T Chesler; Alexander C Jackson; Yaron M Sigal; Hiroki Yamanaka; Rebecca Grant; Dajan O'Donnell; Roger A Nicoll; Nirao M Shah; David Julius; Allan I Basbaum Journal: J Neurosci Date: 2011-03-30 Impact factor: 6.167
Authors: Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Matthew R Sapio; John K Neubert; Danielle M LaPaglia; Dragan Maric; Jason M Keller; Stephen J Raithel; Eric L Rohrs; Ethan M Anderson; John A Butman; Robert M Caudle; Dorothy C Brown; John D Heiss; Andrew J Mannes; Michael J Iadarola Journal: J Clin Invest Date: 2018-03-19 Impact factor: 14.808
Authors: Michael J Iadarola; Matthew R Sapio; Stephen J Raithel; Andrew J Mannes; Dorothy Cimino Brown Journal: Pain Date: 2018-10 Impact factor: 7.926